For patients with prostate cancer

Oncotype DX Genomic Prostate Score

Oncotype DX Genomic Prostate Score If you have been diagnosed with low-risk prostate cancer, discussing management options with your doctor is typically the next step. It’s important that you give yourself time to understand what your diagnosis means, and what option will be best for your specific cancer at this specific time.

The Oncotype DX test gives you and your doctor more information for treatment conversations and decisions.

Oncotype DX is a genomic test, meaning that it measures the expression of certain genes in prostate cancer cells. The results of Oncotype DX are reported as a Genomic Prostate Score (GPS), which can help you and your doctor more confidently make decisions about a management plan that’s best for you.

Why your tumor’s gene activity matters

Not all prostate cancers are the same—some are aggressive and require treatment with surgery or radiation therapy. However, many are lower risk and can be managed with regular doctor visits and monitoring called active surveillance—delaying or completely avoiding treatments like surgery or radiation.

It’s important for you to understand your personal risk before deciding on a management plan—with this information in hand you can make a decision that is best suited to helping you live as long and healthy a life as possible. Oncotype DX GPS will help you and your health care team understand your individualized risk to better inform decisions about what happens next—active surveillance or treatment.

What treatment is the best for me?




Some cancers are low risk and may not be aggressive. In these cases, your doctor may recommend Active Surveillance.

Some cancers are high risk and aggressive. These cancers are likely to grow or spread. In these cases, it may be best to act quickly with Immediate Treatment.

Active Surveillance

With Active Surveillance, your cancer will be closely monitored to see if there are any changes in your risk level. Active Surveillance involves regular checkups and ongoing testing, which may include: checking prostate-specific antigen (PSA) levels, regular digital rectal exams, or repeat biopsies. Your cancer may progress while you are on Active Surveillance, but it will remain curable in most cases.

Immediate treatment

Immediate treatment, through options like surgery or radiation therapy, is for patients whose cancer is likely to be aggressive. These cancers have a high risk of adverse pathology, which means they are likely to grow or spread to other parts of your body—this is called metastasis.

How the test can help you

The Oncotype DX GPS test can clarify how the tumor may act and whether it is likely to be aggressive (adverse pathology).

The test also predicts whether you are likely to die from your cancer or have it spread to other parts of your body (metastasis) within 10 years of surgery.

I am eligible?

You could be eligible if you have:

Contact us

For more information about the test contact us.


  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) (Version1.2017). © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed January 10, 2017. To view the most recent and complete version of the guidelines, go to NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
  2. Welty et al. J Urol. 2015. 3. Tosoian et al. J Clin Oncol. 2015. A. Klein et al. Eur Urol. 2014. B. Cullen et al. Eur Urol. 2015. C. Van Den Eeden et al. Eur Urol. 2017. D. Knezevic et al. BMCGenomics. 2013. E. Brand et al. Urology. 2016